Log in | Register

E-mail
Company Name

Ex-head of Johnson &Johnson Japan Unit Accused of Tax Evasion

Loading...
TOKYO, Oct. 7 (Kyodo) — Tokyo tax authorities have filed charges with local prosecutors that a former head of a Japanese unit of U.S. pharmaceutical company Johnson & Johnson allegedly evaded about 60 million yen in income tax by concealing income linked to stock options, sources familiar with the case said Wednesday.

The Tokyo Regional Taxation Bureau has accused 72-year-old Mitsuo Hirose of tax evasion by concealing the roughly 160 million yen he earned between 2005 and 2007 through the stock options he was allowed to exercise as president of Johnson & Johnson Japan Inc. and as an executive of another affiliate.

Hirose, who also was a senior member of the Japan Association of Corporate Executives between fiscal 2001 and 2008, used accounts at U.S. securities firms for his investment activities related to the stock options and deposited profits from stock sales in overseas accounts.

The Tokyo taxation bureau launched its investigation into the suspected tax evasion case after becoming aware that part of the income Hirose did not declare had moved between some of his overseas accounts, according to the sources.
Join the Discussion
Rate Article:  Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Blogs

The Importance of Fundamentals

The Importance of Fundamentals

Aug 31 | Girish Malhotra, PE, President, EPCOT International

Globally, Johnson & Johnson is known for its integrity and product quality. A few years ago they handled the Tylenol situation extremely well and were commended for it. It is astounding that the year 2010 has become a nightmare for them.  

The Quality Control Unit: Invertebrates Need Not Apply

The Quality Control Unit: Invertebrates Need Not Apply

Aug 30 | The QA Pharm

The Quality Control Unit (QCU) is the only pharmaceutical function that has a job description codified in the CGMP regulations. Don’t you find this remarkable? In fact, an entire section is devoted to describing the responsibility of the QCU and how it is to operate within the organization—namely independently.        

Multimedia

Timothy Cote - Office of Orphan Products Development

Aug 13 | Root

From approving medicines to treating snake bites to Cystic Fibrosis - Dr. Tim Cote describes a special office at the FDA, designed to address needs of people with rare diseases. Timothy Cote, M.D. - Director, Office of Orphan Products Development

Charles River Labs On WuXi PharmaTech Acquisition

Charles River Labs On WuXi PharmaTech Acquisition

May 25 | Video

Charles Rivers Laboratories International Chief Officer talks about the recent WuXi PharmaTech acquisition

Biogen Idec - 2010 Facility of the Year Award Winner - Operational Excellence

Biogen Idec - 2010 Facility of the Year Award Winner - Operational Excellence

Apr 27 | Video

Peter Flinn, Biogen Idec's Senior Director, Global Project Engineering talks to Pharmaceutical Processing's Editor-In-Chief Mike Auerbach about the company's Large-Scale Manufacturing Technology Map Project in Research Triangle Park, North Carolina. The project won the 2010 Operational...

MannKind Corporation - 2010 Facility of the Year Award Winner - Equipment & Process Innovation

MannKind Corporation - 2010 Facility of the Year Award Winner - Equipment & Process Innovation

Apr 28 | Video

Juergen Martens, Ph,D. MannKind Corporation's Corporate Vice President and Chief Technical Officer talks to Pharmaceutical Processing's Editor-In-Chief Mike Auerbach durng INTERPHEX2010 about the company's Technosphere Insulin Manufacturing Facility located in Danbury, Connecticut. The...